January 13, 2021 Extraordinary Shareholders Meeting: Wide support for the resolutions submitted to the shareholders’ vote but quorum not met on first convening
January 12, 2021 14:15 ET | Source: GENFIT S.A. GENFIT S.A. Loos, FRANCE
French
Partial buyback and amendment of the bond terms approved by approx. 98% of voting shareholders at this time
Insufficient quorum of 20.63% on first convening, but greater than the 20% quorum required on second convening
Extraordinary Shareholders Meeting will be reconvened on January 25, 2021 with the same agenda
Votes cast on the first convening remain valid for the second convening
Shareholder engagement remains important to ensure the success of this transaction, which aims to decrease the bond debt by nearly half and extend its maturity by 3 years.
OncoZenge expands the board with Hilde Furberg
Search jobs OncoZenge expands the board with Hilde Furberg
OncoZenge AB (publ) (“OncoZenge”), Moberg Pharma AB (publ)’s subsidiary, has at an Extraordinary Shareholders Meeting today resolved on expanding the board with Hilde Furberg ahead of the listing on Nasdaq First North Growth Market, which is planned to take place during the first quarter of 2021.
Hilde Furberg (born 1958) represents Linc AB and is an independent consultant and a professional board member. She has broad senior leadership experience, coming from her over 35 years in sales, marketing, strategy and general management roles in pharmaceuticals and biotechnology. Her experience is in different areas of specialty care, and from small to large global companies. Hilde has worked in companies like Baxter and Genzyme, and she was most recently the European Head of Rare Diseases for Sanofi Genzyme. Hilde has also been a board member of Pr